2020 American Transplant Congress
Biomarkers AFP in Combination with AFP-l3 and DCP Predicts Tumor Progression in Treatment Native HCC Patients
Ochsner Health System, New Orleans, LA
*Purpose: Hepatocellular carcinoma (HCC) treatment with locoregional therapy (LRT) is standard treatment to downstage within Milan Criteria. In this study, we retrospectively analyzed early-stage HCC…2020 American Transplant Congress
In a Murine Model of Acetaminophen-Mediated Liver Injury, Tubastatin-a, An Hdac6-Specific Inhibitor, Improves Survival and Decreases Hepatocellular Injury
*Purpose: Tylenol (APAP) toxicity, due to its narrow therapeutic window, is the leading cause of acute liver failure in the United States, resulting in approximately…2020 American Transplant Congress
Cross-Validation of Performance-Based Frailty against Daily Step Count from Personal Activity Trackers – Refining Prehabilitation Tools in Liver Transplant Candidates
*Purpose: The AST proposed a toolkit to identify frailty in liver transplant (LT) candidates, including the liver frailty index (LFI) and 6-min walk test (6MWT).…2020 American Transplant Congress
Therapeutic Targeting of Bile Acid Metabolism Ameliorates Liver Ischemia/Reperfusion Injury
*Purpose: Farnesoid X receptor (FXR) is the major nuclear receptor of bile acids, which is also involved in the regulation of innate immune responses. As…2020 American Transplant Congress
Utilization of Hepatitis C Viremic Donors in Liver Transplantation. A Single Center Experience
*Purpose: The evolution of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), in the setting of the well recognized organ shortage and the…2020 American Transplant Congress
Hepatocellular Carcinoma Recurrence after Severe Acute Cellular Rejection
1Columbia University Irving Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
*Purpose: The interplay between acute cellular rejection (ACR), immunosuppression and hepatocellular carcinoma (HCC) recurrence in patients who underwent liver transplantation (LT) for HCC is still…2020 American Transplant Congress
Changes in the Development and Incidence of Bacterial Infections – A 16-Year Analysis
Transplant Institute, Henry Ford Hospital, Detroit, MI
*Purpose: Bacterial infections may occur at any time but mostly within the first month post-transplant. However, since recent advances in transplant there has not been…2020 American Transplant Congress
Prognostic Impact of Peritumoral Neutrophil Infiltration on Hepatocellular Carcinoma Recurrence Following Liver Transplantation
1Columbia University Irving Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
*Purpose: Peritumoral neutrophil (PMN) infiltration has been associated with poor clinical outcomes in various tumors; however, its role in hepatocellular carcinoma (HCC) remains understudied. Moreover,…2020 American Transplant Congress
Shorter Waiting Time Was Associated with Higher Risk of Recurrence of Hepatocellular Carcinoma in Liver Transplantation
*Purpose: Liver transplantation (LT) is an established treatment option for hepatocellular carcinoma (HCC). After 6-month waiting rule was implemented, the impact of wait-listing (WL) time…2020 American Transplant Congress
Risk Factors for Hepatic Artery Thrombosis: A Single Center Study with Multiple Surgeons
*Purpose: Hepatic Artery Thrombosis (HAT) is an uncommon complication after liver transplant, but its occurrence can lead to significant and fatal outcomes. Our objective was…
- « Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 180
- Next Page »